The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Does The Forecasted Market Size Of The mRNA Cancer Vaccines And Therapeutics Market Compare Between 2026 And 2030?
The mrna cancer vaccines and therapeutics market size has experienced rapid growth in recent years. It is expected to expand from $71.22 billion in 2025 to $82.67 billion in 2026, achieving a compound annual growth rate (CAGR) of 16.1%. The growth observed in the historical period stems from the successful application of mrna platforms in infectious disease vaccines, breakthroughs in cancer immunology research, a deeper understanding of tumor antigens, early clinical validation of mrna cancer therapies, and increasing public and private funding directed towards oncology innovation.
The mrna cancer vaccines and therapeutics market is projected to experience substantial expansion over the upcoming years. It is anticipated to reach a valuation of $141.51 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 14.4%. This growth during the projection period stems from factors such as the increasing worldwide incidence of cancer, the heightened need for tailored and precise cancer therapies, the enlargement of mRNA production capabilities, a rise in oncology clinical studies utilizing mRNA technologies, and key partnerships between biotechnology and pharmaceutical firms. Key trends identified for the forecast timeframe encompass the increased acceptance of personalized cancer vaccines, the extension of mRNA-based treatments beyond cancer applications, an intensified focus on developing neoantigen-specific vaccines, a broadening clinical pipeline for mRNA cancer immunotherapies, and greater investment in scalable mRNA manufacturing solutions.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17204&type=smp
Which Strategic Drivers Are Supporting The mRNA Cancer Vaccines And Therapeutics Market Development?
The expanding incidence of cancer is anticipated to fuel the expansion of the mRNA cancer vaccine and therapeutic market. Cancer refers to a collection of illnesses marked by the unrestrained proliferation and dissemination of atypical cells, capable of infiltrating and harming healthy tissues. This escalating occurrence of cancer is predominantly linked to elements like inactive lifestyles, inadequate nutritional practices, and exposure to environmental pollutants, all of which heighten the likelihood of developing numerous forms of cancer. mRNA cancer vaccines and therapeutics are vital for enhancing cancer treatment, facilitating tailored, precise immune reactions that aid the body in more effectively recognizing and eradicating cancer cells, consequently bettering patient outcomes. For example, in January 2024, data from the American Cancer Society, Inc., a US-based cancer advocacy organization, projects that the United States will experience more than 611,000 cancer-related deaths in 2024, which averages out to over 1,600 fatalities daily. Consequently, the increasing prevalence of cancer is a key factor propelling the expansion of the mRNA cancer vaccine and therapeutic market.
What Are The Core Segment Classifications In The mRNA Cancer Vaccines And Therapeutics Market?
The mrna cancer vaccines and therapeutics market covered in this report is segmented –
1) By Type: Adeno Carcinomas, Mucinous Carcinomas, Adenosquamous Carcinomas
2) By Application: Cancer, Other Applications
3) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Research Institutes, Other End Users
Subsegments:
1) By Adeno Carcinomas: Lung Adenocarcinomas, Colon Adenocarcinomas, Prostate Adenocarcinomas
2) By Mucinous Carcinomas: Mucinous Ovarian Cancer, Mucinous Breast Cancer, Mucinous Colorectal Cancer
3) By Adenosquamous Carcinomas: Pancreatic Adenosquamous Carcinoma, Cervical Adenosquamous Carcinoma, Esophageal Adenosquamous Carcinoma
Which Trends Are Contributing To Changes In The mRNA Cancer Vaccines And Therapeutics Market?
Leading companies within the mRNA cancer vaccines and therapeutics market are concentrating on creating novel solutions, including personalized neoantigen vaccines, to boost immune responses and better survival rates for cancer patients. These personalized neoantigen vaccines represent cancer treatments tailored individually for each patient, utilizing distinct tumor-specific mutations to prompt the immune system into targeting and eliminating cancer cells. As an example, in July 2023, Merck & Co., Inc., a US-based research-focused biopharmaceutical firm, collaborated with Moderna Therapeutics, Inc., a US-based biotechnology enterprise, to commence a Phase 3 randomized clinical trial (V940-001). This trial aims to assess mRNA-4157 (V940) when combined with KEYTRUDA (pembrolizumab) as an adjuvant therapy for individuals suffering from resected high-risk (Stage IIB-IV) melanoma. This current investigation builds upon encouraging outcomes from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial, which demonstrated significant advantages of the combination therapy compared to KEYTRUDA by itself in decreasing the likelihood of recurrence and distant metastasis. The ongoing Phase 3 trial seeks to validate these earlier findings through the evaluation of relapse-free survival and distant metastasis-free survival, designated as primary and secondary endpoints in that order.
Which Companies Are Engaged In The mRNA Cancer Vaccines And Therapeutics Market Environment?
Major companies operating in the mrna cancer vaccines and therapeutics market are BioNTech SE, Moderna Therapeutics Inc., CureVac N.V., Arcturus Therapeutics Holdings Inc., Immatics Biotechnologies GmbH, Argos Therapeutics Inc., Anima Biotech, Translate Bio, eTheRNA Immunotherapies NV, Gritstone bio Inc., Neon Therapeutics, Codiak BioSciences, Cartesian Therapeutics, Replimune Group Inc., Precision BioSciences, Acuitas Therapeutics, Ethris GmbH, Strand Therapeutics, Crown Bioscience, Roche (Hoffmann-La Roche AG)
Access The Complete mRNA Cancer Vaccines And Therapeutics Market Report:
Which Region Is The Dominant Market In The mRNA Cancer Vaccines And Therapeutics Market?
North America was the largest region in the mRNA cancer vaccination and therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mrna cancer vaccines and therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access mRNA Cancer Vaccines And Therapeutics Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=17204&type=smp
Browse Through More Reports Similar to the Global mRNA Cancer Vaccines And Therapeutics Market 2026, By The Business Research Company
Mrna Cancer Vaccines And Therapeutics Market Report 2026
Therapeutic Bcg Vaccines Market Report 2026
https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report
Mrna Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model